Precision Medicine Group (PMG), a Bethesda, MD-based specialized services company supporting innovative approaches to drug development and commercialization, is to receive a $275m investment.
The transaction is being led by Berkshire Partners and TPG Growth with participation from co-founders and management team as well as original investors Oak Investment Partners and J.H. Whitney.
The company intends to use the funds to continue to expand its global presence and provide additional scale to accelerate the development, approval and commercial success of innovative treatments.
Founded in 2012 and led by Mark Clein, CEO, and Ethan Leder, Chairman, Precision provides an integrated infrastructure that supports pharmaceutical and life sciences companies as they develop new products in the age of precision medicine.
The company today has over 1,000 employees and 22 locations in the U.S., Canada and Europe.